Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1996 1
1998 18
1999 7
2000 11
2001 16
2002 30
2003 40
2004 43
2005 37
2006 58
2007 36
2008 42
2009 38
2010 34
2011 35
2012 24
2013 23
2014 24
2015 30
2016 22
2017 15
2018 11
2019 15
2020 12
2021 17
2022 8
2023 12
2024 9
2025 7
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

620 results

Results by year

Filters applied: . Clear all
Page 1
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 3 …
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate o …
Donepezil for Fatigue and Psychological Symptoms in Post-COVID-19 Condition: A Randomized Clinical Trial.
Nakamura K, Kondo K, Oka N, Yamakawa K, Ie K, Goto T, Fujitani S. Nakamura K, et al. JAMA Netw Open. 2025 Mar 3;8(3):e250728. doi: 10.1001/jamanetworkopen.2025.0728. JAMA Netw Open. 2025. PMID: 40094666 Free PMC article. Clinical Trial.
Between December 14, 2022, and March 31, 2024, adult patients within 52 weeks of the onset of COVID-19 and with a global binary fatigue score of 4 or greater on the Chalder Fatigue Scale were randomized into a donepezil or a placebo group. EXPOSURE: The intervention was co …
Between December 14, 2022, and March 31, 2024, adult patients within 52 weeks of the onset of COVID-19 and with a global binary fatigue scor …
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. Rogers SL, et al. Neurology. 1998 Jan;50(1):136-45. doi: 10.1212/wnl.50.1.136. Neurology. 1998. PMID: 9443470 Clinical Trial.
Patients were randomly assigned to treatment with placebo (n = 162), 5 mg/d donepezil (n = 154), or 10 mg/d donepezil (n = 157) for 24 weeks followed by a 6-week, single-blind placebo washout. ...Cognitive function, as measured by the ADAS-cog, was significantly imp …
Patients were randomly assigned to treatment with placebo (n = 162), 5 mg/d donepezil (n = 154), or 10 mg/d donepezil (n = 157 …
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Tariot PN, et al. JAMA. 2004 Jan 21;291(3):317-24. doi: 10.1001/jama.291.3.317. JAMA. 2004. PMID: 14734594 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled clinical trial of 404 patients …
OBJECTIVE: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatm …
Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial.
Lee W, Kim M. Lee W, et al. Medicine (Baltimore). 2024 Jun 14;103(24):e38067. doi: 10.1097/MD.0000000000038067. Medicine (Baltimore). 2024. PMID: 38875437 Free PMC article. Clinical Trial.
The ASCOMALVA trial, a combination of donepezil and choline alfoscerate, slowed cognitive decline in Alzheimer disease. This study aims to replicate the effect by combining donepezil with other nootropics currently used in South Korea. METHODS: The 119 patients with …
The ASCOMALVA trial, a combination of donepezil and choline alfoscerate, slowed cognitive decline in Alzheimer disease. This study ai …
Durable recovery from amblyopia with donepezil.
Wu C, Gaier ED, Nihalani BR, Whitecross S, Hensch TK, Hunter DG. Wu C, et al. Sci Rep. 2023 Jun 22;13(1):10161. doi: 10.1038/s41598-023-34891-5. Sci Rep. 2023. PMID: 37349338 Free PMC article. Clinical Trial.
Motivated by these promising findings, we sought to determine whether donepezil, a commercially available AChEI, can enable recovery in older children and adults with residual amblyopia. ...Gains were maintained 10 weeks after cessation of donepezil and were similar …
Motivated by these promising findings, we sought to determine whether donepezil, a commercially available AChEI, can enable recovery …
Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial.
Montero-Odasso M, Speechley M, Chertkow H, Sarquis-Adamson Y, Wells J, Borrie M, Vanderhaeghe L, Zou GY, Fraser S, Bherer L, Muir-Hunter SW. Montero-Odasso M, et al. Eur J Neurol. 2019 Apr;26(4):651-659. doi: 10.1111/ene.13872. Epub 2018 Dec 26. Eur J Neurol. 2019. PMID: 30565793 Clinical Trial.
We aimed to determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic neurotransmission, on gait performance in mild cognitive impairment (MCI). ...Per-protocol analyses showed that all three DTCs improved in the donepezil group, along with …
We aimed to determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic neurotransmission, on gait performanc …
Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial.
Osataphan N, Phrommintikul A, Leemasawat K, Somwangprasert A, Apaijai N, Suksai S, Sirikul W, Gunaparn S, Chattipakorn SC, Chattipakorn N. Osataphan N, et al. Sci Rep. 2023 Aug 7;13(1):12759. doi: 10.1038/s41598-023-40061-4. Sci Rep. 2023. PMID: 37550350 Free PMC article. Clinical Trial.
Metformin and donepezil did not attenuate hsTnI elevation, LVEF or GLS reduction. There was no significant change in NT-proBNP level. Mitochondrial respiratory dysfunction was observed in the placebo and donepezil groups. However, metformin preserved mitochondrial r …
Metformin and donepezil did not attenuate hsTnI elevation, LVEF or GLS reduction. There was no significant change in NT-proBNP level. …
Dengzhan shengmai capsule combined with donepezil hydrochloride in the treatment of Alzheimer's disease: preliminary findings, randomized and controlled clinical trial.
Huang P, He XY, Xu M. Huang P, et al. Rev Assoc Med Bras (1992). 2021 Feb;67(2):190-194. doi: 10.1590/1806-9282.67.02.20200378. Rev Assoc Med Bras (1992). 2021. PMID: 34287475 Free article. Clinical Trial.
OBJECTIVE: To observe the effects of Dengzhan Shengmai capsule combined with donepezil hydrochloride on cognitive function, daily living ability, and safety in patients with Alzheimer's disease. ...CONCLUSIONS: Dengzhan Shengmai capsule combined with donepezil hydro …
OBJECTIVE: To observe the effects of Dengzhan Shengmai capsule combined with donepezil hydrochloride on cognitive function, daily liv …
Donepezil improved memory in multiple sclerosis in a randomized clinical trial.
Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Krupp LB, et al. Neurology. 2004 Nov 9;63(9):1579-85. doi: 10.1212/01.wnl.0000142989.09633.5a. Neurology. 2004. PMID: 15534239 Clinical Trial.
The clinician also reported cognitive improvement in almost twice as many donepezil vs placebo patients (p = 0.036). No serious adverse events related to study medication occurred, although more donepezil (34.3%) than placebo (8.8%) subjects reported unusual/abnorma …
The clinician also reported cognitive improvement in almost twice as many donepezil vs placebo patients (p = 0.036). No serious adver …
620 results